285 related articles for article (PubMed ID: 33270549)
1. A hospital-wide initiative to redesign substance use disorder care: Impact on pharmacotherapy initiation.
Wakeman SE; Kane M; Powell E; Howard S; Shaw C; Kehoe L; Rosen J; Quinlan J; Regan S
Subst Abus; 2021; 42(4):767-774. PubMed ID: 33270549
[No Abstract] [Full Text] [Related]
2. Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic.
Wakeman SE; McGovern S; Kehoe L; Kane MT; Powell EA; Casey SK; Yacorps GM; Irvin JR; Rodriguez W; Regan S
J Subst Abuse Treat; 2022 Oct; 141():108848. PubMed ID: 35926256
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
4. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
[TBL] [Abstract][Full Text] [Related]
5. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
6. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
Wiercigroch D; Sheikh H; Hulme J
Subst Abuse Treat Prev Policy; 2020 Jan; 15(1):4. PubMed ID: 31931831
[TBL] [Abstract][Full Text] [Related]
7. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
[TBL] [Abstract][Full Text] [Related]
8. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
Smith A; Hansen J; Colvard M
J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
[TBL] [Abstract][Full Text] [Related]
9. Peer recovery coaches in general medical settings: Changes in utilization, treatment engagement, and opioid use.
Magidson JF; Regan S; Powell E; Jack HE; Herman GE; Zaro C; Kane MT; Wakeman SE
J Subst Abuse Treat; 2021 Mar; 122():108248. PubMed ID: 33509420
[TBL] [Abstract][Full Text] [Related]
10. The relationship between dissociative symptoms and the medications used in the treatment of opioid use disorder.
Gainer DM; Crawford TN; Fischer KB; Wright MD
J Subst Abuse Treat; 2021 Feb; 121():108195. PubMed ID: 33357605
[TBL] [Abstract][Full Text] [Related]
11. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
12. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
13. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
14. Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.
Boudreau DM; Lapham G; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Campbell CI; Rossom RC; Binswanger IA; Yarborough BJ; Arnsten JH; Cunningham CO; Glass JE; Murphy MT; Zare M; Hechter RC; Ahmedani B; Braciszewski JM; Horigian VE; Szapocznik J; Samet JH; Saxon AJ; Schwartz RP; Bradley KA
J Subst Abuse Treat; 2020 Mar; 112S():41-48. PubMed ID: 32220410
[TBL] [Abstract][Full Text] [Related]
15. Implementation of a Medication for Addiction Treatment (MAT) and Linkage Program by Leveraging Community Partnerships and Medical Toxicology Expertise.
Beauchamp GA; Laubach LT; Esposito SB; Yazdanyar A; Roth P; Lauber P; Allen J; Boateng N; Shaak S; Burmeister DB
J Med Toxicol; 2021 Apr; 17(2):176-184. PubMed ID: 33146875
[TBL] [Abstract][Full Text] [Related]
16. The case for a medication first approach to the treatment of opioid use disorder.
Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
[No Abstract] [Full Text] [Related]
17. Bridging Recovery Initiative Despite Gaps in Entry (BRIDGE): study protocol for a randomized controlled trial of a bridge clinic compared with usual care for patients with opioid use disorder.
Marcovitz DE; White KD; Sullivan W; Limper HM; Dear ML; Buie R; Edwards DA; Chastain C; Kast KA; Lindsell CJ;
Trials; 2021 Oct; 22(1):757. PubMed ID: 34717736
[TBL] [Abstract][Full Text] [Related]
18. Office-Based Addiction Treatment Retention and Mortality Among People Experiencing Homelessness.
Fine DR; Lewis E; Weinstock K; Wright J; Gaeta JM; Baggett TP
JAMA Netw Open; 2021 Mar; 4(3):e210477. PubMed ID: 33662132
[TBL] [Abstract][Full Text] [Related]
19. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
[TBL] [Abstract][Full Text] [Related]
20. The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use disorder.
Ober AJ; Murray-Krezan C; Page K; Friedmann PD; Chan Osilla K; Ryzewicz S; Huerta S; Mazer MW; Leamon I; Messineo G; Watkins KE; Nuckols T; Danovitch I
Addict Sci Clin Pract; 2022 Jul; 17(1):39. PubMed ID: 35902888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
